Hebei Nengqian Chemical Import and Export Co., LTD
Assessed Supplier Enterprise Certification
- Assessed
Supplier - 4th
years
Assessed Supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86 18233902561
Mobile: +86 18233902561
Tel: +86 18233902561
Fax: 4001020630
URL: https://www.nengqianchemical.com/
Province/state: Hebei
City: Handan
Street: No.1722, Block C, Yangguang Xinzhuo Plaza, 256 Renmin West Road, Fuxing District, Handan City, Hebei Province
MaxCard:
Ms.AnnaCAS NO.39262-14-1
medical grade(1-50)Kilogrammedical grade(50-500)Kilogram
OEM Supply Superior Quality 99% Cytosine CAS 71-30-7
Basic Information:
Cytosine (C) is one of the four main bases found in DNA and RNA, along with adenine, guanine, and thymine (uracil in RNA).
Cytosine reagent is used in a wide variety of research applications, as an enzyme-substrate or precursor of effector molecules such as cytosine sugars.
| Product Name: | Cytosine |
| Synonyms: | 4-AMINO-2(1H)-PYRIMIDINONE;4-AMINO-2(1)-PYRIMIDONE;4-AMINO-2-PYRIMIDINOL;4-AMINO-2-OXO-1,2-DIHYDROPYRIMIDINE;4-AMINO-2-HYDROXYPYRIMIDINE;2-Oxy-4-amino pyrimidine;AURORA KA-682;CYTOSINE |
| CAS: | 71-30-7 |
| MF: | C4H5N3O |
| MW: | 111.1 |
| Molecular Formula | C36H62O8 |
| Molar Mass | 622.88 |
| Density | 1.19 |
| Melting Point | 181～183℃ |
| Boling Point | 723.1±60.0 °C(Predicted) |
| Specific Rotation(α) | (c, 1 in MeOH)+39 |
| Solubility | Soluble in DMSO, pyridine, insoluble in petroleum ether, chloroform and other organic solvents. |
| Appearance | White powder |
| pKa | 12.94±0.70(Predicted) |
| Storage Condition | 2-8℃ |
| MDL | MFCD07772261 |
| Physical and Chemical Properties | White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from ginseng rhizome, Gynostemma pentaphyllum. |
| In vitro study | Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and proinflammatory cytokines. Ginsenoside C-K suppresses the expression of proinflammatory cytokines by downregulating the activities of IRAK-1, MAPKs, IKK-α, and NF-κB in LPS-treated murine peritoneal macrophages. Ginsenoside C-K also suppresses the expression of iNOS and COX-2 by inhibiting NF-κB signaling in LPS-stimulated RAW264.7 cells. In zymosan-treated bone-marrow-derived macrophages (BMDMs) and RAW264.7 cells, Ginsenoside C-K inhibits inflammatory responses by negatively regulating the secretion of proinflammatory cytokines, the activation of MAPKs, and the generation of ROS. In addition, anti-inflammatory activity of Ginsenoside C-K has been observed in LPS-stimulated microglial cells. Ginsenoside C-K hinders inflammatory responses by controlling both the generation of ROS and the activities of MAPKs, NF-κB, and AP-1. Ginsenoside C-K, a major metabolite of ginsenosides in the gastrointestinal tract, inhibits NF-κB signaling in a PXR-dependent manner. Ginsenoside C-K is shown to promote recovery of dextran sulfate sodium (DSS) -induced colitis by suppressing NF-κB activation. Ginsenoside C-K significantly reduces TNF-α-induced upregulation of IL-1β and iNOS mRNA levels, and restores the mRNA levels of PXR and CYP3A4 in LS174T cells. Ginsenoside C-K, one of the intestinal metabolites of 20(S)-protopanaxadiol derivatives, exhibits an inhibition against the activity of CYP2C9 in human liver microsomes with an IC 50 value of 32.0±3.6 μM, a weak inhibition against the activity of CYP2A6 in human liver microsomes with an IC 50 value of 63.6±4.2 μM, and an even weaker inhibition against the activity of CYP2D6 in human liver microsomes with an IC 50 value of more than 100 μM. |
| In vivo study | The weight of the collagen-induced arthritis (CIA) mice increases slowly and is significantly less than that of the normal DBA/1 mice beginning on d 3 after injection of the emulsion. Ginsenoside C-K (28, 56, and 112 mg/kg) mice recover their weight by d 32 after the emulsion injection. Ginsenoside C-K (56 and 112 mg/kg) and Methotrexate (MTX)-treated (2 mg/kg) mice show significantly increased body weight on d 50 as compared with CIA mice. Hind paw-swelling began on d 24 post-immunization. CIA mice are treated from d 28 to d 50. Arthritis scores are measured every 4 d beginning on d 24. Ginsenoside C-K (56 and 112 mg/kg) significantly reduces the arthritis scores of the mice on d 51. |